Additional file 3 of Anticancer bispecific antibody R&D advances: a study focusing on research trend worldwide and in China

Abstract

Additional file 3. Fig. S2: The MOA of bsAbs clinical trials. (A-B) The number of MOAs of international companies and China-initiated or involved companies, respectively. (C-D) Surface plot of MOA of international companies and China-initiated or involved companies, respectively